- Home
- RM vs ACRS Comparison
RM vs ACRS Comparison
Compare RM & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RM | ACRS |
|---|---|---|
| Founded | 1987 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.4M | 314.2M |
| IPO Year | 2012 | 2015 |
Fundamental Metrics
Financial Performance| Metric | RM | ACRS |
|---|---|---|
| Price | $37.58 | $4.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $30.00 | $9.75 |
| AVG Volume (30 Days) | 43.5K | ★ 2.9M |
| Earning Date | 02-04-2026 | 02-26-2026 |
| Dividend Yield | ★ 3.13% | N/A |
| EPS Growth | ★ 71.26 | N/A |
| EPS | ★ 4.13 | N/A |
| Revenue | ★ $610,145,000.00 | $15,742,000.00 |
| Revenue This Year | $16.34 | N/A |
| Revenue Next Year | $7.05 | N/A |
| P/E Ratio | $9.29 | ★ N/A |
| Revenue Growth | ★ 9.60 | N/A |
| 52 Week Low | $25.41 | $1.05 |
| 52 Week High | $46.00 | $4.89 |
Technical Indicators
Market Signals| Indicator | RM | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 43.43 | 80.59 |
| Support Level | $35.99 | $2.61 |
| Resistance Level | $38.75 | $4.89 |
| Average True Range (ATR) | 1.28 | 0.38 |
| MACD | -0.18 | 0.21 |
| Stochastic Oscillator | 24.45 | 85.21 |
Price Performance
Historical ComparisonAbout RM Regional Management Corp.
Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. It is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.